AB-FUBINACA
 | |
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H21FN4O2 |
| Molar mass | 368.40 g/mol g·mol−1 |
| 3D model (JSmol) | |
| |
| |
AB-FUBINACA is a drug that acts as a potent agonist for the cannabinoid receptors, with Ki values of 0.9 nM at CB1 and 23.2 nM at CB2, and EC50 values of 1.8 nM at CB1 and 3.2 nM at CB2.[1][2][3] It was originally developed by Pfizer in 2009 as an analgesic medication,[4] but was never pursued for human use. Subsequently in 2012, this compound was discovered as an ingredient in synthetic cannabis blends in Japan,[5] along with a related compound AB-PINACA which had not previously been reported.
Side effects
AB-FUBINACA has been linked to hospitalizations and deaths due to its use.[6][7]
Legality
In January 2014, AB-FUBINACA was designated as a Schedule I controlled substance in the United States.[8]
AB-FUBINACA is an Anlage II controlled substance in Germany as of November 2014.[9]
As of October 2015 AB-FUBINACA is a controlled substance in China.[10]
See also
References
- ^ Samuel D Banister; Michael Moir; Jordyn Stuart; Richard C Kevin; Katie E Wood; Mitchell Longworth; Shane M Wilkinson; Corinne Beinat; Alxendra S Buchanan; Michelle Glass; Mark Connor; Iain S McGregor; Michael Kassiou (July 2015). "The pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA and 5F-ADBICA". ACS Chemical Neuroscience. 6 (9): 1546–1559. doi:10.1021/acschemneuro.5b00112. PMID 26134475.
- ^ Hsin-Hung Chen; Aybike Dip; Mostafa Ahmed; Michael L. Tan; Jeffrey P. Walterscheid; Hua Sun; Ba-Bie Teng; Ashraf Mozayani (April 2016). "Detection and Characterization of the Effect of AB-FUBINACA and its Metabolites in a Rat Model". Journal of Cellular Biochemistry. 117 (4): 1033–1043. doi:10.1002/jcb.25421. PMID 26517302.
- ^ Svante Vikingsson; Henrik Gréen; Linda Brinkhagen; Shahzabe Mukhtar; Martin Josefsson (November 2015). "Identification of AB-FUBINACA metabolites in authentic urine samples suitable as urinary markers of drug intake using liquid chromatography quadrupole tandem time of flight mass spectrometry". Drug Testing and Analysis. doi:10.1002/dta.1896. PMID 26560240.
- ^ Buchler IP et al, INDAZOLE DERIVATIVES. WO 2009/106982
- ^ Uchiyama, N.; Matsuda, S.; Wakana, D.; Kikura-Hanajiri, R.; Goda, Y. (January 2013). "New cannabimimetic indazole derivatives, N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide (AB-PINACA) and N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA) identified as designer drugs in illegal products". Forensic Toxicology. 31 (1): 93–100. doi:10.1007/s11419-012-0171-4.
- ^ Jordan Trecki; Roy R. Gerona; Michael D. Schwartz (July 2015). "Synthetic Cannabinoid–Related Illnesses and Deaths". New England Journal of Medicine. 373 (2): 103–107. doi:10.1056/NEJMp1505328. PMID 26154784.
- ^ Janez Klavž; Maksimiljan Gorenjak; Martin Marinšek (August 2016). "Suicide attempt with a mix of synthetic cannabinoids and synthetic cathinones: Case report of non-fatal intoxication with AB-CHMINACA, AB-FUBINACA, alpha-PHP, alpha-PVP and 4-CMC". Forensic Science International. 265: 121–124. doi:10.1016/j.forsciint.2016.01.018. PMID 26890319.
- ^ "Schedules of Controlled Substances: Temporary Placement of Four Synthetic Cannabinoids Into Schedule I". Drug Enforcement Administration, Department of Justice. 10 January 2014. Retrieved 21 July 2015.
- ^ "Gesetz über den Verkehr mit Betäubungsmitteln (Betäubungsmittelgesetz - BtMG) Anlage II (zu § 1 Abs. 1) (verkehrsfähige, aber nicht verschreibungsfähige Betäubungsmittel)" (in German). Retrieved 22 June 2015.
- ^ "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Retrieved 1 October 2015.
 | This cannabinoid related article is a stub. You can help Wikipedia by expanding it. |